Skip to main content
. 2015 Mar 2;169(5):672–682. doi: 10.1111/bjh.13338

Figure 3.

Figure 3

Progression‐free survival and overall survival. (A) Kaplan–Meier curve of estimated progression‐free survival (median, 8∙5 months and 6∙3 months in the mLSG15‐plus‐mogamulizumab and mLSG15 arms, respectively). (B) Kaplan–Meier curve of estimated overall survival (median, not achieved in either arm). The median follow‐up periods in the mLSG15‐plus‐mogamulizumab and mLSG15 arms were 413 days (range, 63–764 days) and 502 days (range, 62–794 days), respectively.